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Abstract
We provide a basic overview of inheritance, fertility and influence of IBD and pregnancy, 
therapy in pregnancy and childbirth options. A crucial factor for good results is the 
degree of inflammation at the time of conception and during pregnancy. If the disease 
is inactive, there is no decrease in fertility and no greater risk of deterioration of disease 
in pregnancy and pregnancy does not differ from the normal population. The opposite 
situation occurs if there is a pregnancy at the time of disease activity. Then, in up to 75% 
of pregnancy courses with big problems, fertility declines, inflammation also worsens 
and the risk of exacerbations increases during pregnancy. This aggravates the course of 
pregnancy and childbirth and has a negative effect on the fetus. Therefore, it is necessary 
to plan for a longer period of disease stabilization and continue chronic medication and 
not discontinue drugs for the fear of negative impact of medications on fetal develop-
ment. Commonly used drugs such as aminosalicylates, corticosteroids, immunosuppres-
sants and biological therapy appear to be safe and well tolerated during pregnancy. The 
method of delivery is different for each individual and depends on the form and location 
of the inflammation and the preceding operations.
Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, pregnancy, 
childbirth, breastfeeding
1. Introduction
Inflammatory bowel disease (IBD) is a chronic bowel inflammation of unknown origin, which 
includes Crohn’s disease (CD) and ulcerative colitis (UC). The incidence in our population 
has increased, the incidence of UC is 10.4/100,000 and the incidence of CD is 5.6/100,000. IBD 
affects young adults in their fertile age, 50% of patients are diagnosed under the age of 35 and 
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a quarter of patients get pregnant after they have been diagnosed with IBD. Young women 
are often concerned about the effect of IBD on their fertility, development of the fetus and as 
well about the effect of the pregnancy on their disease. They are interested in the effect of the 
chronic medication used during the pregnancy, management of the birth and possibility of 
breastfeeding. In the past, patients have been advised not to get pregnant, existing strategies 
of treating IBD makes the pregnancy possible and safe for the mother and the child.
2. Genetics and IBD
IBD is multifactorially determined. The risk for a child with a parent with an IBD is 2–13 times 
higher than the risk in the normal population [1]. A child of a parent with IBD has a 5% risk 
for CD and a 1.6% for UC. If both parents have IBD, the risk increases up to 37% [2, 3].
3. Fertility and IBD
Infertility of women with IBD ranges between 7 and 12%, which is in line with the normal 
population [4–7]. The fertility can decrease with the following conditions:
• An active inflammation (can affect the Fallopian tubes and the ovaries, in the perianal area 
it can cause dyspareunia)
• Surgery before the pregnancy (IPAA—ileo pouch anal anastomosis—is connected with 
lower fertility because of scarring in the area around the adnexae)
• Medication that affects men’s fertility such as methotrexate, sulfasalazine [1, 9, 10]
4. The effects of IBD on pregnancy
Multiple studies on the effects of IBD on pregnancy, development and growth of the fetus, 
have come to a conflicting conclusions most likely due to disparate conditions of the indi-
vidual studies. All the studies agree that the key factor for a successful pregnancy is a func-
tion of whether the disease is active at the time of conception. Patients with an inactive IBD 
(minimum 12 months without clinical, laboratory and endoscopic signs of an active inflam-
matory process) are not in a higher risk of bad perinatological results. On the other hand, if 
the disease is active, up to 75% of pregnancies are connected with a high number of problems 
and relatively high risk of abortion, preterm birth or hypotrophy of the fetus. Therefore, it is 
necessary to plan the pregnancy while the disease is in remission [1, 4–6, 8]. The activity of 
the disease at the time of conception leads to a higher risk of fetal loss and preterm deliveries. 
Also, activity of the disease during the pregnancy is associated with lower fetal weight and as 
well with a preterm delivery [1, 3, 8, 9, 10]. Pregnancy loss affects 12.2% of patients with IBD 
as compared to 9.9% in the normal population. Miscarriages are more common in cases where 
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the patient has an intestinal resection before the pregnancy. The length of the resected tissue 
and activity of the disease are proportional to a higher risk of miscarriage [6]. The percentage 
of preterm deliveries (<g.h. 37) is around 8% in the Czech Republic in the normal popula-
tion, studies describe higher risk of preterm deliveries in the group of people with IBD, the 
risk is 1.87 times higher, which is 11.5–16% [6]. The risk of low fetal weight (<2500 g) is two 
times higher, which is explained by undernourishment of the mother in the time of relapse, 
especially if there are repeated exacerbations in the course of the pregnancy. This occurs more 
often in diseased with the CD than the UC, Although some studies have found a connection 
between congenital malformations (especially a cleft palate and malformations of the urinary 
tract) and the mother’s UC, this suspicion was not confirmed in extensive studies. Most of 
the studies show that IBD is not connected with a risk of congenital malformations. The rate 
of malformations ranges between 1 and 4.8% of newborns, which is the same range as in the 
normal population. More serious malformations were more often found in a group with a 
severe course of the disease during the pregnancy compared to the ones in relapse. After con-
sidering the grade of disease, no study was able to prove that any medication used (corticoids, 
azathioprine and mesalazine) affects the result of pregnancy [5].
5. The effect of pregnancy on IBD
There is no proof to suggest that pregnancy worsens the disease; therefore, there is no rea-
son to end the pregnancy. On the contrary, there are studies that have demonstrated posi-
tive effects and long-term improvement of IBD (impact of the pregnancy on the immune 
system) shown decrease of relapses in the following 3 years [2]. Development of IBD dur-
ing the pregnancy is correlated with the activity of disease at the time of conception. If the 
disease is inactive at the time of conception, then the pregnancy goes without bigger prob-
lems in the majority of the diseased, only around one-third of patients have a relapse dur-
ing the pregnancy, which is the same number as in a group of nonpregnant women in the 
course of 9 months. In two-thirds of the patients, the disease stays in inactive state during the 
whole pregnancy [1, 4, 6, 8]. On the other hand, if the IBD is active at the time of conception, 
two-thirds of the patients have a persistent disease and even an aggravation of the disease. 
Therapy plays an important role in pregnancy by keeping the disease in remission; therefore, 
it is recommended that the therapy should not be stopped due to the fear of side effects to 
pregnancy.
6. Therapy in pregnancy
The majority of the drugs used for the treatment of IBD are considered to be safe during the 
pregnancy and breastfeeding [3]. Analysis of 19 retrospective studies has shown that the medi-
cation commonly used for therapy of IBD (aminosalicylates—ASA, corticoids, immunosup-
pressants and immunotherapy) does not significantly increase the incidence of stillborn, ectopic 
pregnancy, hypotrophy of the fetus or miscarriage. While using these drugs, the  congenital 
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anomalies were more often seen, which is probably connected to the activity of the disease and 
not to the therapy. Both methotrexate and thalidomide are clearly contraindicated [1].
If the therapy is able to keep the disease inactive, it is recommended not to stop and continue 
the therapy during the whole pregnancy because the benefits outweigh the risks of the con-
servative therapy and the danger of relapse after completing the therapy.
7. The mode of delivery
The percentage (44%) of the Cesarean section is higher in the group of patients with IBD than 
in normal population [3]. Recent population studies from Sweden have shown that women 
with the UC without any surgery in the past had two times higher risk of elective Cesarean 
section, even though vaginal birth is the safest way for the mother and the child. Additional 
studies have also shown that the Cesarean sections are mostly performed on the basis of 
patient’s or the doctor’s preference, but not from a real indication. Even though some doc-
tors think that all the patients with IBD should have a Cesarean section, it seems reasonable 
to make the vaginal birth possible for the women with inactive or in the moderate stage of 
the disease. The decision about the mode of the delivery should be strictly individual and it 
should be an agreement among the mother, the obstetrician, the gastroenterologist and the 
surgeon [6].
Cesarean section is definitely indicated when there is an active perianal disease with abscesses 
and fistulas or active rectal disease (proctitis in UC and CD) with consideration of the protec-
tion of the anal sphincter. IPAA or ileorectal anastomosis is considered as a relative indication 
for the Cesarean section, the guidelines about the mode of delivery after IPAA are not uni-
form, and both ways are described. With a consideration of a protection of the anal sphincter 
and keeping the pouch continence, the Cesarean section is preferred. Patients with the IPAA 
have, due to the surgery, a border continence of stool and that is closely related to an intact 
sphincter and the function of the pelvic floor. The function of the pouch is affected already in 
the third trimester and it goes back to the original shape during 6 months after the delivery. In 
the vaginal birth, the pudendal nerves can be affected due to the pressure in the second stage 
of labor or in the forceps delivery, which can lead to more frequent stools. In the long-term 
observation (5 years), it is observed that after the vaginal birth, the function of the pouch wors-
ens faster especially in the births with the higher risks of obstetric injuries (instrumental labor, 
episiotomy, the fetal weight above 4000 g, emergent Cesarean section, second stage of labor 
longer than 2 h) In the majority of the patients, the primary Cesarean section is chosen. Other 
reason for that is as well the emergency Cesarean section from the obstetrics indication can be 
very risky because of abdominal adhesions after previous surgeries [1, 3, 9, 10]. Vaginal birth 
should be allowed only to women without the signs of rectal and perianal forms of the disease 
[6]. Traumatic changes of the perianal area can be a cause of long-term festering complications 
or fistulas, preforming of episiotomy can induce the perianal lesions in the future course of 
the disease in 20% [5]. If the woman with IBD has a vaginal birth, it is appropriate to avoid 
episiotomy; however, it is better to perform an episiotomy than a spontaneous uncontrollable 
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damage. Vaginal birth is also possible in the patients with colostomy or ileostomy and it is not 
associated with a higher risk of the complications with the stomies [1, 6].
8. Conclusion
IBD affects women in the fertile age with consequences to their fertility, pregnancy and breast-
feeding. The disease and the pregnancy affect each other, and the development of the disease 
and the pregnancy is determined by the activity of inflammation at the time of conception. 
Patients who are in remission at the time of conception will most likely stay in the remission 
during the pregnancy. On the other hand, 70% of the patients with an active inflammation 
at the time of conception will stay in that shape or even get worse during the pregnancy. 
Women with an active IBD are at a higher risk of adverse results of the pregnancy, whereas 
the women with inactive disease can expect normal course and good results of the pregnancy. 
That is why it is crucial to plan their pregnancy during remission, and not to cut out the anti-
inflammatory and immunosuppressant therapy put in place before the pregnancy. Most of 
the medication used in treatment of IBD is considered to be safe at the time of pregnancy 
and breastfeeding, but more studies are needed. Patients with IBD can have vaginal delivery, 
whereas patients with the perianal lesions, patients with affected rectum and patients after 
the reconstructive surgery with IPAA should deliver by the Cesarean section.
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